Latest news

We are excited and proud to announce that in the 2022/23 financial year, we are committing a further $5 million to neurological research!

Ian is usually pretty confident of a win in the MSWA Lottery but this year was different – he thought he had missed out on a ticket entirely. You can imagine his surprise when he received the call congratulating him on winning the life changing $3.8 million Applecross Grand Prize Package.

For Australians living with MS, REBIF will no longer be available on the Pharmaceutical Benefits Scheme (PBS) from 1 December 2022.

Who might be these invisible heroes? These people are commonly known as ‘carers’, but ‘common’ and ‘ordinary’ they are not.

On 14 October 2022, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended that Evusheld not be listed on the Pharmaceutical Benefits Scheme (PBS). However, this may be revised in the future and access will remain through current schemes.

"We are so grateful that MSWA looks after us"
44-year-old Jasmin Franklin was born with a rare condition called Klippel-Feil Syndrome. Remarkably, the diagnosis took 40 years to be found.

Watch Jasmin's incredible story…

Vumerity® (diroximel fumarate) will be listed under the Pharmaceutical Benefit Scheme (PBS).

Ros Harman has announced her resignation from the MSWA Board after 18 years of service and valued contribution.

MSWA is proud to be funding this important West Australian research, led by Professor Bruni Meloni, that will potentially provide the first effective treatment to minimise the damage that occurs in the early phases of stroke.

The survey, where 1,748 Australians (of which 525 are living with MS) participated, revealed there is a disconnect between expectations and workplace realities for those with a health condition.